āĻĒāϰāĻŦāϰā§āϤ⧠āĻāĻĒāĻĒāϰāĻŦāϰā§āϤ⧠āĻāĻžāĻāĻĄ
āĻāĻāĻ āĻŽā§āĻĄāĻŋāĻā§āϞ āĻĄāĻŋāĻāĻžāĻāϏā§āϰ āĻāĻĢāĻĄāĻŋāĻ āϰā§āĻā§āϞā§āĻļāύ
āĻļāĻŋāϞā§āĻĒ
āϏā§āϏāĻžāĻāĻāĻŋ āĻāĻžāĻāĻĄ
An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.
āĻāĻ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāĻāĻž āĻļā§āύā§āύāĻāĻāĻ-āĻŦāϰā§āĻŖāĻŋāϤ ¡ ~3 min
FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.
A PCCP is a planned change-management component of a medical-device marketing submission. FDAâs August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to âretrain as neededâ do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDAâs current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.
A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.
A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.
A change to a modelâs intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.
A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.
FDAâs guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the deviceâs update method changes.
āĻĢā§āϰāĻŋ āύāĻŋāĻāĻāϞā§āĻāĻžāϰ
āĻĒā§āϰāϤāĻŋ āϏāĻĒā§āϤāĻžāĻšā§āϰ āĻāĻžāĻā§āϰ āĻĻāĻŋāύ āϏāĻāĻžāϞ⧠āϤāĻŋāύāĻāĻŋ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻāĻāĻ āϏā§āĻā§āϰāĻŋ, āϏāĻšāĻ āĻāĻāϰā§āĻāĻŋāϤ⧠āϞā§āĻāĻžāĨ¤ āĻāĻŋāϰāĻāĻžāϞā§āϰ āĻāύā§āϝ āĻĢā§āϰāĻŋ, āĻā§āύ⧠āĻŦāĻŋāĻā§āĻāĻžāĻĒāύ āύā§āĻāĨ¤
āĻĒā§āϰāϤāĻŋ āϏāĻĒā§āϤāĻžāĻšā§āϰ āĻāĻžāĻā§āϰ āĻĻāĻŋāύ⧠āĻāĻāĻāĻŋ āĻāĻŽā§āϞāĨ¤ āĻāĻ āĻā§āϞāĻŋāĻā§āĻ āĻāύāϏāĻžāĻŦāϏā§āĻā§āϰāĻžāĻāĻŦ āĻāϰā§āύāĨ¤ āĻāĻŽāϰāĻž āĻāĻāύā§āĻ āĻāĻĒāύāĻžāϰ āĻ āĻŋāĻāĻžāύāĻž āĻŦāĻŋāĻā§āϰāĻŋ āĻŦāĻž āĻļā§ā§āĻžāϰ āĻāϰāĻŋ āύāĻžāĨ¤
āύāĻŋāĻā§āĻā§ āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύ
āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāϤā§āϤāϰā§āϰ āϤāĻžā§āĻā§āώāĻŖāĻŋāĻ āĻĢāĻŋāĻĄāĻŦā§āϝāĻžāĻ, āĻāĻŦāĻ āĻā§āϰā§āϏ āĻĒāĻžāϏ āĻāϰāĻžāϰ āĻĒāϰ āϝāĻžāĻāĻžāĻāϝā§āĻā§āϝ āĻāĻāĻĄāĻŋ āϏāĻš āĻāĻāĻāĻŋ āĻļā§ā§āĻžāϰāϝā§āĻā§āϝ āϏāĻžāϰā§āĻāĻŋāĻĢāĻŋāĻā§āĻāĨ¤
āĻĢā§āϰāĻŋ āĻāĻāĻ āĻļāĻŋāĻā§āώāĻžāĻā§ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āύāĨ¤ AI Understanding āĻāĻāĻāĻŋ 501(c)(3) āĻ āϞāĻžāĻāĻāύāĻ āĻĒā§āϰāϤāĻŋāώā§āĻ āĻžāύ â āĻā§āύ⧠āĻŦāĻŋāĻā§āĻāĻžāĻĒāύ āύā§āĻ, āĻā§āύ⧠āĻĒā§āĻā§āĻžāϞ āύā§āĻ, āĻāĻāύā§āĻ āύāĻžāĨ¤ āĻāĻāĻāĻŋ āĻĻāĻžāύ āĻāϰā§āύ
An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.
FDAâs final guidance describes planned modifications, a protocol for implementing them, and an assessment of their impact.
FDA reviews the PCCP as part of the relevant marketing submission.
The plan can support specified future modifications without a new marketing submission for each change, if they follow the authorized plan.
A change outside the authorized scope needs a regulatory assessment and may require a new submission.
FDA identifies its tailored final guidance as issued in August 2025.
āĻļāĻŋāĻāϤ⧠āĻĨāĻžāĻā§āύ
āĻāĻ āĻŦāĻŋāώāϝāĻŧā§āϰ āĻāύā§āϝ āĻŦāĻžāĻāĻžāĻ āĻāϰāĻž āĻāϰāĻ āĻāĻžāĻāĻĄ
āĻĒāϰāĻŦāϰā§āϤ⧠āĻāĻĒāĻĒāϰāĻŦāϰā§āϤ⧠āĻāĻžāĻāĻĄ
āĻāĻāĻ āĻŽā§āĻĄāĻŋāĻā§āϞ āĻĄāĻŋāĻāĻžāĻāϏā§āϰ āĻāĻĢāĻĄāĻŋāĻ āϰā§āĻā§āϞā§āĻļāύ
āĻļāĻŋāϞā§āĻĒ